New pill cuts bad cholesterol by 60 percent: Could it become a game-changer in heart attack prevention?
A new oral medication has shown LDL reductions of about 55.8%. The experimental drug, Enlicitide, developed by Merck, was presented at the American Heart Association Scientific Sessions 2025, and early results have excited cardiologists around the world.Unlike existing PCSK9 inhibitors, which require injections, Enlicitide is the first oral PCSK9 inhibitor, taken as a once-daily pill….